Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Single and repeated administration of neuroleptic drugs to rats: Effects on striatal dopamine-sensitive adenylate cyclase and locomotor activity produced by tranylcypromine and L-tryptophan or L-dopa

  • 33 Accesses

  • 43 Citations

Abstract

Injection of tranylcypromine and L-tryptophan results in rats displaying behavioural changes including hyperactivity, probably due to stimulation of post-synaptic 5-hydroxytryptamine (5-HT) receptors. Increased locomotor activity of a different type is elicited by injection of tranylcypromine and L-dopa, a procedure which increased dopaminergic function in the brain. It has now been demonstrated that the neuroleptic drugs, chlorpromazine, α-flupenthixol, haloperidol and spiroperidol block both syndromes. The inhibition produced by these drugs on 5-HT-induced hyperactivity is probably because a dopaminergic system is involved in the behavioural expression of the 5-HT induced hyperactivity. The structurally related drugs with no neuroleptic activity (ethopropazine, promethazine and β-flupenthixol) are without effect on these hyperactivity syndromes. Also ineffective were the neuroleptics pimozide and clozapine.

Striatal dopamine sensitive adenylate cyclase activity in vitro was inhibited by the administration of chlorpromazine (100 mg/kg) in vivo.

Rats treated for 4 or more days with chlorpromazine, α-flupenthixol, spiroperidol and haloperidol subsequently showed enhanced locomotor activity in response to tranylcypromine and L-Dopa. Administration of those drugs which did not block hyperactivity acutely did not result in enhancement. Only chlorpromazine, when given for 4 days, enhanced the hyperactivity response following tranylcypromine and L-tryptophan, probably because the drug also blocks 5-HT receptors.

In rats displaying enhanced behavioural responses no evidence was found for enhanced sensitivity of striatal adenylate cyclase to dopamine.

This is a preview of subscription content, log in to check access.

References

  1. Boullin, D. J., Grahame-Smith, D. G., Grimes, R. P. J., Woods, H. F.: Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlopromazine and its metabolites. Brit. J. Pharmacol. 53, 121–125 (1975a)

  2. Boullin, D. J., Woods, H. F., Grimes, R. P. J., Grahame-Smith, D. G., Wiles, D., Gelder, M. G., Kolakowska, T.: Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Brit. J. clin. Pharmacol. 2, 29–35 (1975b)

  3. Bradley, P. B., Wolstencroft, J. H., Hösli, L., Avanzino, G. L.: Neuronal basis for the central actions of chlorpromazine. Nature (Lond.) 212, 1425–1427 (1966)

  4. Brown, B. L., Albano, J. D. M., Ekins, R. P., Sgherzi, A. M., Tampion, W.: A simple and sensitive saturation assay method for the measurement of Adenosine 3′ 5′-cyclic monophosphate. Biochem. J. 121, 561–562 (1971)

  5. Buus Lassen, J.: Inhibition of 4, α-dimethyl-m-tyramine (H 77/77)-induced hypermotility in rats by single and repeated administration of chlorpromazine, haloperidol, clozapine and thioridazine. Psychopharmacologia (Berl.) 43, 25–29 (1975)

  6. Clement-Cormier, Y. L., Kebabian, J. W., Petzold, G. L., Greengard, P.: Dopamine sensitive adenylate cyclase in mammalian brain: a possible site of action of antipsychotic drugs. Proc. nat. Acad. Sci. (Wash.) 171, 1113–1117 (1974)

  7. Costall, B., Naylor, R. J.: Neuroleptic antagonism of dyskinetic phenomena. Europ. J. Pharmacol. 33, 301–312 (1975)

  8. Crow, T. J., Gilbe, D.: Dopamine antagonism and antischizophrenic potency of neuroleptic drugs. Nature New Biol. 245, 27–28 (1973)

  9. De Maio, D.: Clozapin, a novel major tranquilliser. Arzneimittel-Forsch. 22, 919–923 (1972)

  10. Gianutsos, G., Drawbaugh, R. B., Hynes, M. D., Lal, H.: Behavioural evidence for dopaminergic supersensitivity after chronic haloperidol. Life Sci. 14, 887–898 (1974)

  11. Grahame-Smith, D. G.: Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J. Neurochem. 18, 1053–1066 (1971a)

  12. Grahame-Smith, D. G.: Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy N,N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor. Brit. J. Pharmacol. 43, 856–864 (1971b)

  13. Green, A. R., Grahame-Smith, D. G.: The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. Neuropharmacology 13, 949–959 (1974)

  14. Green, A. R., Grahame-Smith, D. G.: The effect of drugs on the factors controlling the functional activity of brain 5-hydroxytryptamine. Nature (Lond.) 260, 487–491 (1976)

  15. Green, A. R., Kelly, P. H.: Evidence concerning the involvement of 5-hydroxytryptamine in the locomotor activity produced by amphetamine or tranylcypromine plus L-Dopa. Brit. J. Pharmacol. 57, 141–147 (1976)

  16. Green, A. R., Tordoff, A. F. C., Bloomfield, M. R.: Elevation of brain GABA concentrations with amino-oxycetic acid; effect on the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. J. neural Trans. (in press, 1976)

  17. von Gross, H., Langner, E.: Das Neuroleptikum 100-129/HF-1854 (Clozapin) in der Psychiatrie. Int. Pharmacopsychiat. 4, 220–230 (1970)

  18. von Gross, H., Langner, E.: Das Wirkungprofil eines chemisch neuartigen Breitbandneuroleptikums der Dibenzodiazepingruppe. Wien. med. Wschr. 40, 814–816 (1966)

  19. Haase, H. J., Blannenburg-Zahn, M., Koester, H., Neuhaus, B.: Zur Frage der therapeutischen Wirksamkeit eines Neuroleptikums bei chronisch Schizophrenen mit Dosierungen oberhalb und unterhalb der “neuroleptischen Schwelle” (am Beispiel des Neuroleptikums Pimozide). Int. Pharmacopsychiat. 3, 1–12 (1969)

  20. Horn, A. S., Cuello, A. E., Miller, R. J.: Dopamine in the mesolimbic system of the rat brain: endogenous levels and the effects of drugs on the uptake mechanism and stimulation of adenylate cyclase activity. J. Neurochem. 22, 265–270 (1974)

  21. von Hungen, K., Roberts, S., Hill, D. F.: Serotonin sensitive adenylate cyclase activity in immature rat brain. Brain Res. 84, 257–267 (1975)

  22. Ionescu, R., Nica, S. V., Oproiu, L., Niturad, A., Tudorache, B.: Double-blind study in psychopathic behaviour disorders (clozapine and pericyanine). Pharmacopsychiat. 6, 294–299 (1973)

  23. Iversen, L. L.: Dopamine receptors in the brain. Science 188, 1084–1089 (1975a)

  24. Iversen, L. L.: Summing up. Advanc. Neurol. 9, 415–418 (1975b)

  25. Iwatsubo, K., Clouet, D. H.: Dopamine-sensitive adenylate cyclase of the caudate nucleus of rats treated with morphine or haloperidol. Biochem. Pharmacol. 24, 1499–1503 (1975)

  26. Jacobs, B. L.: Effect of two dopamine receptor blockers on a serotonin-mediated behavioural syndrome in rats. Europ. J. Pharmacol. 27, 363–366 (1974)

  27. Karobath, M. E.: Tricyclic antidepressive drugs and dopaminesensitive adenylate cyclase from rat brain striatum. Europ. J. Pharmacol. 30, 159–163 (1975)

  28. Kebabian, J. W., Clement-Cormier, Y. C., Petzold, G. L., Greengard, P.: Chemistry of dopamine receptors. Advanc. Neurol 9, 1–11 (1975)

  29. Kebabian, J. W., Petzold, G. L., Greengard, P.: Dopamine-sensitive adenylate cyclase in the caudate nucleus of the rat brain and its similarity to the “dopamine receptor”. Proc. nat. Acad. Sci. (Wash.) 69, 2145–2149 (1972)

  30. Kelly, P. H.: Unilateral 6-hydroxydopamine lesions of nigrostriatal or mesolimbic dopamine-containing terminals and drug induced rotation in rats. Brain Res. 100, 163–169 (1975)

  31. Kelly, P. H., Miller, R. J.: The interaction of neuroleptic and muscarinic agents with central dopaminergic systems. Brit. J. Pharmacol. 54, 115–121 (1975)

  32. Kelly, P. H., Seviour, P. W., Iversen, S. D.: Amphetamine and apomorphine responses in the rat, 6-OHDA lesions of the nucleus acumbens septi and corpus striatum. Brain Res. 94, 507–522 (1975)

  33. Klawans, H. L., D'Amico, D. J., Patel, B. C.: Behavioural supersensitivity to 5-hydroxytryptophan induced by chronic methysergide pretreatment. Psychopharmacologia (Berl.) 44, 297–300 (1975)

  34. Laduron, P.: Limiting factors in the antagonism of neuroleptic drugs on dopamine-sensitive adenylate cyclase. J. Pharm. Pharmacol. 28, 250–251 (1976)

  35. Manian, A. A., Efron, D. H., Goldberg, M. A.: A comparative pharmacological study of a series of monohydroxylated and methoxylated chlorpromazine derivatives in the central nervous system. Life Sci. 4, 2425–2438 (1965)

  36. Miller, R. J., Hiley, C. R.: Antimuscarinic properties of neuroleptic drugs and drugs induced parkinsonism. Nature (Lond.) 248, 596–597 (1974)

  37. Miller, R. J., Hiley, R.: Antimuscarinic actions of neuroleptic drugs. Advanc. Neurol. 9, 141–154 (1975)

  38. Miller, R. J., Horn, A. S., Iversen, L. L.: The action of neuroleptic drugs on dopamine stimulated adenosine 3′ 5′-monophosphate production in rat neostriatum and limbic forebrain. Molec. Pharmacol. 10, 759–766 (1974)

  39. Mishra, R. K., Gardner, E. L., Katzman, R., Makman, M. H.: Enhancement of dopamine-stimulated adenylated cyclase activity in rat caudate after lesions in substantia nigra: evidence for denervation supersensitivity. Proc. nat. Acad. Sci. (Wash.) 71, 3883–3887 (1974)

  40. Moore, K. E., Thornburg, J. E.: Drug induced dopaminergic supersensitivity. Advanc. Neurol. 9, 93–104 (1975)

  41. Nybäck, H., Schubert, J., Sedvall, G.: Effect of apomorphine and pimozide on synthesis and turnover of labelled catecholamines in mouse brain. J. Pharm. Pharmacol. 22, 622–624 (1970)

  42. Pellegrino, L. J., Cushman, A. J.: A stereotaxic atlas of the rat brain. New York: Appleton-Century-Crofts, 1967

  43. Posner, H. S., Hearst, E., Taylor, W. L., Losmides, G. J.: Model metabolites of chlopromazine and promazine: relative activities in some pharmacological and behavioural tests. J. Pharmacol. exp. Ther. 137, 84–90 (1962)

  44. Snyder, S. H., Greenberg, D. E., Yamamura, H.: Antischizophrenic drug and brain cholinergic receptors: affinity for muscarinic sites predicts extrapyramidal effects. Arch. gen. Psychiat. 31, 58–62 (1974)

  45. Sterkmans, P., Brugmans, J., Gevers, F.: The clinical efficacy of pimozide in chronic psychiatic patients. Clin. Trials. J. 5, 1107–1112 (1968)

  46. Stille, G., Hippius, H.: Kritische Stellungnahme zum Begriff der Neuroleptika. Pharmacopsychiat. 4, 182–191 (1971)

  47. Stille, G., Lauener, H., Eichenberger, E.: The pharmacology of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo (v.e) (1,4) diazepine (clozapine). Farmaco, Edprat. 26, 603–625 (1971)

  48. Thornburg, J. E., Moore, K. E.: The relative importance of dopaminergic and noradrenergic neuronal systems for the stimulation of locomotor activity induced by amphetamine and other drugs. Neuropharmacology 12, 853–866 (1973)

  49. Turano, P., Turner, W. J., Manian, A. A.: Thin layer chromatography of chlorpromazine metabolites. Attempts to identify each of the metabolites appearing in blood, urine and feces of chronically medicated schizophrenics. J. Chromatogr. 75, 277–293 (1973)

  50. Ungerstedt, U.: Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta physicol scand. 83, Suppl. 367, 49–68 (1971)

  51. Ungerstedt, U., Ljungberg, T., Hoffer, B., Siggins, G.: Dopaminergic supersensitivity in the striatum. Advanc. Neurol. 9, 57–65 (1975)

  52. von Voigtlander, P. F., Boukma, S. J., Johnson, G. A.: Dopaminergic denervation supersensitivity and dopamine stimulated adenyl cyclase activity. Neuropharmacology 12, 1081–1086 (1973)

  53. von Voigtlander, P. F., Losey, E. G., Triezenberg, H.: Increased sensitivity to dopaminergic agents after chronic neuroleptic treatment. J. Pharmacol. exp. Ther. 193, 88–94 (1975)

  54. Wilk, S., Watson, E., Stanley, M. E.: Differential sensitivity of two dopaminergic structures in rat brain to haloperidol and clozapine. J. Pharmacol. exp. Ther. 195, 265–270 (1975)

Download references

Author information

Correspondence to D. J. Heal.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Heal, D.J., Green, A.R., Boullin, D.J. et al. Single and repeated administration of neuroleptic drugs to rats: Effects on striatal dopamine-sensitive adenylate cyclase and locomotor activity produced by tranylcypromine and L-tryptophan or L-dopa. Psychopharmacology 49, 287–300 (1976). https://doi.org/10.1007/BF00426832

Download citation

Keywords

  • Haloperidol
  • Clozapine
  • Locomotor Activity
  • Adenylate Cyclase
  • Chlorpromazine